ESSA Pharma Slides As Insider Purchases Lose Another US$211k
ESSA Pharma Slides As Insider Purchases Lose Another US$211k
Insiders who bought US$289.3k worth of ESSA Pharma Inc.'s (NASDAQ:EPIX) stock at an average buy price of US$5.17 over the last year may be disappointed by the recent 74% decrease in the stock. This is not good as insiders invest based on expectations that their money will appreciate over time. However, as a result of recent losses, their original investment is now worth only US$78.4k.
購買了價值28.93萬美元的ESSA Pharma Inc.股份的內部人士s(納斯達克股票代碼:EPIX)股票去年的平均買入價爲5.17美元,可能會對該股最近下跌74%感到失望。這並不好,因爲內部人士的投資是基於他們的資金會隨着時間的推移而升值的預期。但是,由於最近的虧損,他們最初的投資現在僅價值78.4萬美元。
While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, we would consider it foolish to ignore insider transactions altogether.
儘管我們絕不會建議投資者僅根據公司董事的所作所爲做出決定,但我們認爲完全忽視內幕交易是愚蠢的。
ESSA Pharma Insider Transactions Over The Last Year
去年 ESSA Pharma 的內幕交易
In the last twelve months, the biggest single purchase by an insider was when Independent Director Franklin Berger bought US$135k worth of shares at a price of US$5.73 per share. That means that an insider was happy to buy shares at above the current price of US$1.40. It's very possible they regret the purchase, but it's more likely they are bullish about the company. To us, it's very important to consider the price insiders pay for shares. Generally speaking, it catches our eye when insiders have purchased shares at above current prices, as it suggests they believed the shares were worth buying, even at a higher price.
在過去的十二個月中,內部人士最大的一次收購是獨立董事富蘭克林·伯傑以每股5.73美元的價格購買了價值13.5萬美元的股票。這意味着內部人士樂於以高於當前1.40美元的價格購買股票。他們很可能會後悔這次收購,但他們更有可能看好該公司。對我們來說,考慮內部人士爲股票支付的價格非常重要。總的來說,當內部人士以高於當前的價格購買股票時,它會引起我們的注意,因爲這表明他們認爲即使價格更高,也值得買入。
ESSA Pharma insiders may have bought shares in the last year, but they didn't sell any. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. By clicking on the graph below, you can see the precise details of each insider transaction!
ESSA Pharma內部人士可能在去年購買了股票,但他們沒有出售任何股票。您可以看到下圖所示的去年的內幕交易(公司和個人)。通過點擊下面的圖表,你可以看到每筆內幕交易的確切細節!
ESSA Pharma is not the only stock that insiders are buying. For those who like to find small cap companies at attractive valuations, this free list of growing companies with recent insider purchasing, could be just the ticket.
ESSA Pharma並不是內部人士唯一買入的股票。對於那些喜歡尋找估值誘人的小盤股公司的人來說,這份最近有內幕收購的成長型公司的免費清單可能只是入場券。
Insider Ownership Of ESSA Pharma
ESSA Pharma的內部所有權
Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. A high insider ownership often makes company leadership more mindful of shareholder interests. Our data suggests ESSA Pharma insiders own 2.2% of the company, worth about US$1.4m. I generally like to see higher levels of ownership.
查看公司的內部持股總量可以幫助你了解他們是否與普通股股東保持一致。較高的內部所有權通常會使公司領導層更加關注股東的利益。我們的數據顯示,ESSA Pharma內部人士擁有該公司2.2%的股份,價值約140萬美元。我通常希望看到更高的所有權級別。
So What Do The ESSA Pharma Insider Transactions Indicate?
那麼,ESSA製藥業內幕交易表明了什麼?
There haven't been any insider transactions in the last three months -- that doesn't mean much. On a brighter note, the transactions over the last year are encouraging. We'd like to see bigger individual holdings. However, we don't see anything to make us think ESSA Pharma insiders are doubting the company. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. Every company has risks, and we've spotted 4 warning signs for ESSA Pharma (of which 2 shouldn't be ignored!) you should know about.
在過去的三個月中,沒有任何內幕交易——這並不意味着什麼。好消息是,去年的交易令人鼓舞。我們希望看到更多的個人持股。但是,我們認爲沒有任何東西可以讓我們認爲ESSA Pharma內部人士對該公司表示懷疑。因此,雖然了解內部人士在買入或賣出方面的所作所爲很有幫助,但了解特定公司面臨的風險也很有幫助。每家公司都有風險,我們已經發現了ESSA Pharma的4個警告信號(其中2個不容忽視!)你應該知道。
If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.
如果你想看看另一家公司——一家財務狀況可能優越的公司——那麼千萬不要錯過這份免費的股本回報率高、債務低的有趣公司的名單。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
就本文而言,內部人士是指向相關監管機構報告其交易的個人。我們目前只考慮公開市場交易和私下處置的直接利益,不包括衍生品交易或間接權益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接聯繫我們。或者,也可以發送電子郵件至編輯團隊 (at) simplywallst.com。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。